: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

Oliena Studio

Stroke and language recovery: 9000+ videos

Español • Italiano • Sardu • English | PDF+

Leukemia

Free Subscription

Articles published in Leukemia
Retrieve available abstracts of 415 articles:
HTML format
Text format

Single Articles

October 2019

BACCARANI M, Iacobucci I, Chiaretti S, Foa' R, et al
In Ph+BCR-ABL1(P210+) acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent.
Leukemia. 2019 Oct 8. pii: 10.1038/s41375-019-0591.
PubMed Text format

TUMINO N, Besi F, Di Pace AL, Mariotti FR, et al
PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation.
Leukemia. 2019 Oct 4. pii: 10.1038/s41375-019-0585.
PubMed Text format

HALPERN AB, Howard NP, Othus M, Hendrie PC, et al
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm.
Leukemia. 2019 Oct 4. pii: 10.1038/s41375-019-0586.
PubMed Text format

SAUER MG, Lang PJ, Albert MH, Bader P, et al
Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial.
Leukemia. 2019 Oct 2. pii: 10.1038/s41375-019-0584.
PubMed Text format Abstract available

MEYER T, Jahn N, Lindner S, Rohner L, et al
Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1).
Leukemia. 2019 Oct 1. pii: 10.1038/s41375-019-0578.
PubMed Text format Abstract available

September 2019

THASTRUP M, Marquart HV, Levinsen M, Grell K, et al
Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study.
Leukemia. 2019 Sep 18. pii: 10.1038/s41375-019-0570.
PubMed Text format Abstract available

AZADNIV M, Myers JR, McMurray HR, Guo N, et al
Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support.
Leukemia. 2019 Sep 6. pii: 10.1038/s41375-019-0568.
PubMed Text format Abstract available

ZHANG Z, Li L, Wu C, Yin G, et al
Inhibition of Slug effectively targets leukemia stem cells via the Slc13a3/ROS signaling pathway.
Leukemia. 2019 Sep 6. pii: 10.1038/s41375-019-0566.
PubMed Text format Abstract available

EFFICACE F, Stagno F, Iurlo A, Breccia M, et al
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.
Leukemia. 2019 Sep 2. pii: 10.1038/s41375-019-0563.
PubMed Text format Abstract available

August 2019

ARRUGA F, Bracciama V, Vitale N, Vaisitti T, et al
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.
Leukemia. 2019 Aug 29. pii: 10.1038/s41375-019-0571.
PubMed Text format Abstract available

ENYA CHEN YC, Burgess M, Mapp S, Mollee P, et al
PI3K-p110delta contributes to antibody responses by macrophages in chronic lymphocytic leukemia.
Leukemia. 2019 Aug 28. pii: 10.1038/s41375-019-0556.
PubMed Text format Abstract available

AGRAWAL M, Schwarz P, Giaimo BD, Bedzhov I, et al
Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML).
Leukemia. 2019 Aug 28. pii: 10.1038/s41375-019-0551.
PubMed Text format

SMITH LD, Minton AR, Blunt MD, Karydis LI, et al
BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia.
Leukemia. 2019 Aug 28. pii: 10.1038/s41375-019-0557.
PubMed Text format

BHATNAGAR B, Eisfeld AK, Kohlschmidt J, Mrozek K, et al
Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21.
Leukemia. 2019 Aug 28. pii: 10.1038/s41375-019-0560.
PubMed Text format Abstract available

BACCARANI M, Rosti G, Soverini S
Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type.
Leukemia. 2019 Aug 27. pii: 10.1038/s41375-019-0562.
PubMed Text format Abstract available

BOSCH F, Cantin G, Cortelezzi A, Knauf W, et al
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study.
Leukemia. 2019 Aug 27. pii: 10.1038/s41375-019-0554.
PubMed Text format Abstract available

WEISBERG E, Meng C, Case A, Sattler M, et al
Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.
Leukemia. 2019 Aug 27. pii: 10.1038/s41375-019-0552.
PubMed Text format

CAZZOLA A, Schlegel C, Jansen I, Bochtler T, et al
TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia.
Leukemia. 2019 Aug 23. pii: 10.1038/s41375-019-0550.
PubMed Text format Abstract available

HIXON JA, Andrews C, Kashi L, Kohnhorst CL, et al
New anti-IL-7Ralpha monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.
Leukemia. 2019 Aug 22. pii: 10.1038/s41375-019-0531.
PubMed Text format Abstract available

KIM JC, Zuzarte PC, Murphy T, Chan-Seng-Yue M, et al
Cryptic genomic lesions in adverse-risk acute myeloid leukemia identified by integrated whole genome and transcriptome sequencing.
Leukemia. 2019 Aug 21. pii: 10.1038/s41375-019-0546.
PubMed Text format

OFRAN Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, et al
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia.
Leukemia. 2019 Aug 21. pii: 10.1038/s41375-019-0548.
PubMed Text format

AWADA H, Rahman S, Durrani J, Asad MF, et al
Leukemia evolving from paroxysmal nocturnal hemoglobinuria.
Leukemia. 2019 Aug 20. pii: 10.1038/s41375-019-0555.
PubMed Text format

KREUZER KA, Furman RR, Stilgenbauer S, Dubowy RL, et al
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.
Leukemia. 2019 Aug 19. pii: 10.1038/s41375-019-0533.
PubMed Text format

SHEM-TOV N, Peczynski C, Labopin M, Itala-Remes M, et al
Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT.
Leukemia. 2019 Aug 19. pii: 10.1038/s41375-019-0544.
PubMed Text format Abstract available

July 2019

WANG S, Ge M, Cui J, Qiao Z, et al
Diminished interaction between mutant NOTCH1 and the NuRD corepressor complex upregulates CCL17 in chronic lymphocytic leukemia.
Leukemia. 2019 Jul 24. pii: 10.1038/s41375-019-0526.
PubMed Text format

ADVANI PG, Schonfeld SJ, Curtis RE, Dores GM, et al
Risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study.
Leukemia. 2019 Jul 24. pii: 10.1038/s41375-019-0520.
PubMed Text format

WANG H, Zhao D, Nguyen LX, Wu H, et al
Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.
Leukemia. 2019 Jul 23. pii: 10.1038/s41375-019-0522.
PubMed Text format Abstract available

CAO J, Cheng H, Shi M, Wang G, et al
Humanized CD19-specific chimeric antigen-receptor T-cells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia.
Leukemia. 2019 Jul 15. pii: 10.1038/s41375-019-0516.
PubMed Text format

DE SMITH AJ, Walsh KM, Morimoto LM, Francis SS, et al
Heritable variation at the chromosome 21 gene ERG is associated with acute lymphoblastic leukemia risk in children with and without Down syndrome.
Leukemia. 2019 Jul 11. pii: 10.1038/s41375-019-0514.
PubMed Text format

June 2019

BRANFORD S, Kim DDH, Apperley JF, Eide CA, et al
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.
Leukemia. 2019 Jun 17. pii: 10.1038/s41375-019-0512.
PubMed Text format Abstract available

STIEF SM, Hanneforth AL, Weser S, Mattes R, et al
Loss of KDM6A confers drug resistance in acute myeloid leukemia.
Leukemia. 2019 Jun 14. pii: 10.1038/s41375-019-0497.
PubMed Text format Abstract available

GIMENEZ N, Schulz R, Higashi M, Aymerich M, et al
Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia.
Leukemia. 2019 Jun 13. pii: 10.1038/s41375-019-0507.
PubMed Text format Abstract available

ANGENENDT L, Bormann E, Pabst C, Alla V, et al
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia.
Leukemia. 2019 Jun 10. pii: 10.1038/s41375-019-0505.
PubMed Text format Abstract available

BARTH J, Abou-El-Ardat K, Dalic D, Kurrle N, et al
LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML.
Leukemia. 2019;33:1411-1426.
PubMed Text format Abstract available

LYNCH JR, Salik B, Connerty P, Vick B, et al
JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.
Leukemia. 2019;33:1400-1410.
PubMed Text format Abstract available

DUBOIS A, Furstoss N, Calleja A, Zerhouni M, et al
LAMP2 expression dictates azacytidine response and prognosis in MDS/AML.
Leukemia. 2019;33:1501-1513.
PubMed Text format Abstract available

SAENZ DT, Fiskus W, Manshouri T, Mill CP, et al
Targeting nuclear beta-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
Leukemia. 2019;33:1373-1386.
PubMed Text format Abstract available

May 2019

TACHIBANA T, Kanda J, Ishizaki T, Najima Y, et al
Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis.
Leukemia. 2019 May 30. pii: 10.1038/s41375-019-0494.
PubMed Text format Abstract available

ARMENTEROS-MONTERROSO E, Zhao L, Gasparoli L, Brooks T, et al
The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia.
Leukemia. 2019 May 28. pii: 10.1038/s41375-019-0495.
PubMed Text format Abstract available

NII T, Prabhu VV, Ruvolo V, Madhukar N, et al
Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
Leukemia. 2019 May 24. pii: 10.1038/s41375-019-0491.
PubMed Text format Abstract available

HOUSHMAND M, Simonetti G, Circosta P, Gaidano V, et al
Chronic myeloid leukemia stem cells.
Leukemia. 2019 May 24. pii: 10.1038/s41375-019-0490.
PubMed Text format Abstract available

PAN J, Niu Q, Deng B, Liu S, et al
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
Leukemia. 2019 May 20. pii: 10.1038/s41375-019-0488.
PubMed Text format Abstract available

STILGENBAUER S, Aurran Schleinitz T, Eichhorst B, Lang F, et al
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.
Leukemia. 2019 May 14. pii: 10.1038/s41375-019-0475.
PubMed Text format

USTUN C, Le-Rademacher J, Wang HL, Othus M, et al
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.
Leukemia. 2019 May 9. pii: 10.1038/s41375-019-0477.
PubMed Text format Abstract available

BATALLER A, Montalban-Bravo G, Soltysiak KA, Garcia-Manero G, et al
The role of TGFbeta in hematopoiesis and myeloid disorders.
Leukemia. 2019;33:1076-1089.
PubMed Text format Abstract available

POTTER N, Miraki-Moud F, Ermini L, Titley I, et al
Single cell analysis of clonal architecture in acute myeloid leukaemia.
Leukemia. 2019;33:1113-1123.
PubMed Text format Abstract available

WANG TT, Yang J, Zhang Y, Zhang M, et al
IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective gamma-chain cytokines, decreases leukemic T-cell viability.
Leukemia. 2019;33:1243-1255.
PubMed Text format Abstract available

PAGANO MA, Tibaldi E, Molino P, Frezzato F, et al
Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL.
Leukemia. 2019;33:1148-1160.
PubMed Text format Abstract available

April 2019

POLLYEA DA, Tallman MS, de Botton S, Kantarjian HM, et al
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0472.
PubMed Text format Abstract available

DONG Y, Zhao X, Feng X, Zhou Y, et al
SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints.
Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0456.
PubMed Text format Abstract available

KLEIN K, Witalisz-Siepracka A, Maurer B, Prinz D, et al
STAT5B(N642H) drives transformation of NKT cells: a novel mouse model for CD56(+) T-LGL leukemia.
Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0471.
PubMed Text format

LIN M, Nebral K, Gertzen CGW, Ganmore I, et al
JAK2 p.G571S in B-cell precursor acute lymphoblastic leukemia: a synergizing germline susceptibility.
Leukemia. 2019 Apr 9. pii: 10.1038/s41375-019-0459.
PubMed Text format

HYRENIUS-WITTSTEN A, Pilheden M, Falques-Costa A, Eriksson M, et al
FLT3(N676K) drives acute myeloid leukemia in a xenograft model of KMT2A-MLLT3 leukemogenesis.
Leukemia. 2019 Apr 5. pii: 10.1038/s41375-019-0465.
PubMed Text format

EISENWORT G, Sadovnik I, Schwaab J, Jawhar M, et al
Identification of a leukemia-initiating stem cell in human mast cell leukemia.
Leukemia. 2019 Apr 5. pii: 10.1038/s41375-019-0460.
PubMed Text format Abstract available

CHEN YL, Tang C, Zhang MY, Huang WL, et al
Blocking ATM-dependent NF-kappaB pathway overcomes niche protection and improves chemotherapy response in acute lymphoblastic leukemia.
Leukemia. 2019 Apr 2. pii: 10.1038/s41375-019-0458.
PubMed Text format Abstract available

FALINI B, Spinelli O, Meggendorfer M, Martelli MP, et al
IDH1-R132 changes vary according to NPM1 and other mutations status in AML.
Leukemia. 2019;33:1043-1047.
PubMed Text format

POTTER N, Jones L, Blair H, Strehl S, et al
Single-cell analysis identifies CRLF2 rearrangements as both early and late events in Down syndrome and non-Down syndrome acute lymphoblastic leukaemia.
Leukemia. 2019;33:893-904.
PubMed Text format Abstract available

ZABORSKY N, Gassner FJ, Hopner JP, Schubert M, et al
Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.
Leukemia. 2019;33:957-968.
PubMed Text format Abstract available

DORON B, Abdelhamed S, Butler JT, Hashmi SK, et al
Transmissible ER stress reconfigures the AML bone marrow compartment.
Leukemia. 2019;33:918-930.
PubMed Text format Abstract available

BAQUERO P, Dawson A, Mukhopadhyay A, Kuntz EM, et al
Targeting quiescent leukemic stem cells using second generation autophagy inhibitors.
Leukemia. 2019;33:981-994.
PubMed Text format Abstract available

March 2019

EL-JAWAHRI A, Abel GA, Traeger L, Waldman L, et al
Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.
Leukemia. 2019 Mar 28. pii: 10.1038/s41375-019-0449.
PubMed Text format Abstract available

JEBARAJ BMC, Tausch E, Landau DA, Bahlo J, et al
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.
Leukemia. 2019 Mar 25. pii: 10.1038/s41375-019-0446.
PubMed Text format Abstract available

VISHWAKARMA BA, Gudmundsson KO, Oakley K, Han Y, et al
Insertional mutagenesis identifies cooperation between Setbp1 and Mllt3 in inducing myeloid leukemia development.
Leukemia. 2019 Mar 20. pii: 10.1038/s41375-019-0445.
PubMed Text format

LUCAS N, Duchmann M, Rameau P, Noel F, et al
Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.
Leukemia. 2019 Mar 20. pii: 10.1038/s41375-019-0447.
PubMed Text format Abstract available

RADPOUR R, Riether C, Simillion C, Hopner S, et al
CD8(+) T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia.
Leukemia. 2019 Mar 15. pii: 10.1038/s41375-019-0441.
PubMed Text format Abstract available

JANSSEN L, Frambach SJCM, Allard NAE, Hopman MTE, et al
Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Leukemia. 2019 Mar 14. pii: 10.1038/s41375-019-0443.
PubMed Text format

VENDRAMINI E, Bomben R, Pozzo F, Benedetti D, et al
KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.
Leukemia. 2019 Mar 14. pii: 10.1038/s41375-019-0444.
PubMed Text format

PFEIFER H, Cazzaniga G, van der Velden VHJ, Cayuela JM, et al
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
Leukemia. 2019 Mar 11. pii: 10.1038/s41375-019-0413.
PubMed Text format Abstract available

BILL M, Papaioannou D, Karunasiri M, Kohlschmidt J, et al
Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells.
Leukemia. 2019 Mar 11. pii: 10.1038/s41375-019-0429.
PubMed Text format Abstract available

AKKAPEDDI P, Fragoso R, Hixon JA, Ramalho AS, et al
A fully human anti-IL-7Ralpha antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.
Leukemia. 2019 Mar 8. pii: 10.1038/s41375-019-0434.
PubMed Text format Abstract available

HE X, Xiao X, Li Q, Jiang Y, et al
Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL.
Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0437.
PubMed Text format

CANAANI J, Labopin M, Itala-Remes M, Blaise D, et al
Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia.
Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0439.
PubMed Text format Abstract available

BHOJWANI D, Sposto R, Shah NN, Rodriguez V, et al
Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
Leukemia. 2019 Mar 7. pii: 10.1038/s41375-019-0426.
PubMed Text format Abstract available

BASTIAN L, Schroeder MP, Eckert C, Schlee C, et al
PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2019 Mar 6. pii: 10.1038/s41375-019-0430.
PubMed Text format Abstract available

KOTANI S, Yoda A, Kon A, Kataoka K, et al
Molecular pathogenesis of disease progression in MLL-rearranged AML.
Leukemia. 2019;33:612-624.
PubMed Text format Abstract available

KONG G, You X, Wen Z, Chang YI, et al
Downregulating Notch counteracts Kras(G12D)-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm.
Leukemia. 2019;33:671-685.
PubMed Text format Abstract available

BENAJIBA L, Alexe G, Su A, Raffoux E, et al
Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML.
Leukemia. 2019;33:800-804.
PubMed Text format

HUMBERT O, Laszlo GS, Sichel S, Ironside C, et al
Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.
Leukemia. 2019;33:762-808.
PubMed Text format

February 2019

STEINHERZ PG, Seibel NL, Sather H, Ji L, et al
Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group.
Leukemia. 2019 Feb 28. pii: 10.1038/s41375-019-0422.
PubMed Text format Abstract available

BUENO C, Velasco-Hernandez T, Gutierrez-Aguera F, Zanetti SR, et al
CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity.
Leukemia. 2019 Feb 18. pii: 10.1038/s41375-019-0418.
PubMed Text format

MCNEER NA, Philip J, Geiger H, Ries RE, et al
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia.
Leukemia. 2019 Feb 13. pii: 10.1038/s41375-019-0402.
PubMed Text format Abstract available

MROZEK K, Eisfeld AK, Kohlschmidt J, Carroll AJ, et al
Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.
Leukemia. 2019 Feb 8. pii: 10.1038/s41375-019-0390.
PubMed Text format Abstract available

BENARD B, Gentles AJ, Kohnke T, Majeti R, et al
Data mining for mutation-specific targets in acute myeloid leukemia.
Leukemia. 2019 Feb 6. pii: 10.1038/s41375-019-0387.
PubMed Text format Abstract available

GUENOT C, Lacombe F, Allou K, Dumezy F, et al
Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia.
Leukemia. 2019 Feb 5. pii: 10.1038/s41375-019-0393.
PubMed Text format

DAVER N, Schlenk RF, Russell NH, Levis MJ, et al
Targeting FLT3 mutations in AML: review of current knowledge and evidence.
Leukemia. 2019;33:299-312.
PubMed Text format Abstract available

HOURIGAN CS, Gale RP, Walter RB
Refining AML outcome prediction.
Leukemia. 2019;33:283-284.
PubMed Text format

HERNANDEZ-SANCHEZ M, Kotaskova J, Rodriguez AE, Radova L, et al
CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase.
Leukemia. 2019;33:518-558.
PubMed Text format

BORGA C, Park G, Foster C, Burroughs-Garcia J, et al
Simultaneous B and T cell acute lymphoblastic leukemias in zebrafish driven by transgenic MYC: implications for oncogenesis and lymphopoiesis.
Leukemia. 2019;33:333-347.
PubMed Text format Abstract available

CERNA K, Oppelt J, Chochola V, Musilova K, et al
MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
Leukemia. 2019;33:403-414.
PubMed Text format Abstract available

ENGEL N, Rovo A, Badoglio M, Labopin M, et al
European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation.
Leukemia. 2019;33:508-517.
PubMed Text format Abstract available

KAMPEN KR, Sulima SO, Verbelen B, Girardi T, et al
The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL.
Leukemia. 2019;33:319-332.
PubMed Text format Abstract available

January 2019

MASCHMEYER G, De Greef J, Mellinghoff SC, Nosari A, et al
Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).
Leukemia. 2019 Jan 30. pii: 10.1038/s41375-019-0388.
PubMed Text format Abstract available

CHEN R, Zhu M, Chaudhari RR, Robles O, et al
Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.
Leukemia. 2019 Jan 30. pii: 10.1038/s41375-018-0364.
PubMed Text format Abstract available

SHI Y, Wang G, Muhowski EM, McCaw L, et al
Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.
Leukemia. 2019 Jan 29. pii: 10.1038/s41375-019-0381.
PubMed Text format Abstract available

SCHMIDT L, Heyes E, Scheiblecker L, Eder T, et al
CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
Leukemia. 2019 Jan 24. pii: 10.1038/s41375-019-0382.
PubMed Text format Abstract available

KROMBHOLZ CF, Gallego-Villar L, Sahoo SS, Panda PK, et al
Azacitidine is effective for targeting leukemia-initiating cells in juvenile myelomonocytic leukemia.
Leukemia. 2019 Jan 24. pii: 10.1038/s41375-018-0343.
PubMed Text format

MOYSIADIS T, Baliakas P, Rossi D, Catherwood M, et al
Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen b-receptors.
Leukemia. 2019 Jan 24. pii: 10.1038/s41375-018-0322.
PubMed Text format

KOLLMANN S, Grundschober E, Maurer B, Warsch W, et al
Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.
Leukemia. 2019 Jan 24. pii: 10.1038/s41375-018-0369.
PubMed Text format Abstract available

HOFFMANN H, Thiede C, Glauche I, Kramer M, et al
The prognostic potential of monitoring disease dynamics in NPM1-positive acute myeloid leukemia.
Leukemia. 2019 Jan 23. pii: 10.1038/s41375-018-0371.
PubMed Text format

NABINGER SC, Chen S, Gao R, Yao C, et al
Mutant p53 enhances leukemia-initiating cell self-renewal to promote leukemia development.
Leukemia. 2019 Jan 23. pii: 10.1038/s41375-019-0377.
PubMed Text format

BACCARANI M, Castagnetti F, Gugliotta G, Rosti G, et al
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview.
Leukemia. 2019 Jan 23. pii: 10.1038/s41375-018-0341.
PubMed Text format Abstract available

ESTEY E, Othus M, Gale RP
New study-designs to address the clinical complexity of acute myeloid leukemia.
Leukemia. 2019 Jan 22. pii: 10.1038/s41375-018-0363.
PubMed Text format

FIORCARI S, Benatti S, Zucchetto A, Zucchini P, et al
Overexpression of CD49d in trisomy 12 chronic lymphocytic leukemia patients is mediated by IRF4 through induction of IKAROS.
Leukemia. 2019 Jan 18. pii: 10.1038/s41375-018-0296.
PubMed Text format

ALFONSO V, Iaccarino L, Ottone T, Cicconi L, et al
Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia.
Leukemia. 2019 Jan 16. pii: 10.1038/s41375-018-0298.
PubMed Text format

LOPEZ-MILLAN B, Sanchez-Martinez D, Roca-Ho H, Gutierrez-Aguera F, et al
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0353.
PubMed Text format Abstract available

JAWHAR M, Dohner K, Kreil S, Schwaab J, et al
KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0346.
PubMed Text format Abstract available

REDA G, Cassin R, Gentile M, Mauro FR, et al
IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia.
Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0344.
PubMed Text format

OZTURK S, Roessner PM, Schulze-Edinghausen L, Yazdanparast H, et al
Rejection of adoptively transferred Emicro-TCL1 chronic lymphocytic leukemia cells in C57BL/6 substrains or knockout mouse lines.
Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0332.
PubMed Text format

HOANG VT, Verma D, Godavarthy PS, Llavona P, et al
The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia.
Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0358.
PubMed Text format Abstract available

GOUNARI M, Ntoufa S, Gerousi M, Vilia MG, et al
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
Leukemia. 2019 Jan 3. pii: 10.1038/s41375-018-0335.
PubMed Text format

NIYONGERE S, Lucas N, Zhou JM, Sansil S, et al
Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML.
Leukemia. 2019;33:205-216.
PubMed Text format Abstract available

DWIVEDI P, Muench DE, Wagner M, Azam M, et al
Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors.
Leukemia. 2019;33:75-87.
PubMed Text format Abstract available

HAUBNER S, Perna F, Kohnke T, Schmidt C, et al
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
Leukemia. 2019;33:64-74.
PubMed Text format Abstract available

ARAKI M, Yang Y, Imai M, Mizukami Y, et al
Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation.
Leukemia. 2019;33:122-131.
PubMed Text format Abstract available

SCHNEIDT V, Ilecka M, Dreger P, van Zyl DG, et al
Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo.
Leukemia. 2019;33:88-98.
PubMed Text format Abstract available

FRASZCZAK J, Vadnais C, Rashkovan M, Ross J, et al
Reduced expression but not deficiency of GFI1 causes a fatal myeloproliferative disease in mice.
Leukemia. 2019;33:110-121.
PubMed Text format Abstract available

SHIMONI A, Labopin M, Lorentino F, Van Lint MT, et al
Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.
Leukemia. 2019;33:230-239.
PubMed Text format Abstract available

December 2018

ZHAO J, Liang JW, Xue HL, Shen SH, et al
The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia.
Leukemia. 2018 Dec 21. pii: 10.1038/s41375-018-0338.
PubMed Text format Abstract available

VELAZQUEZ-AVILA M, Balandran JC, Ramirez-Ramirez D, Velazquez-Avila M, et al
High cortactin expression in B-cell acute lymphoblastic leukemia is associated with increased transendothelial migration and bone marrow relapse.
Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0333.
PubMed Text format Abstract available

SCHETELIG J, de Wreede LC, van Gelder M, Koster L, et al
Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.
Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0302.
PubMed Text format Abstract available

EFFICACE F, Breccia M, Avvisati G, Cottone F, et al
Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia.
Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0325.
PubMed Text format Abstract available

BORGA C, Foster CA, Iyer S, Garcia SP, et al
Molecularly distinct models of zebrafish Myc-induced B cell leukemia.
Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0328.
PubMed Text format

HANNA BS, Roessner PM, Scheffold A, Jebaraj BMC, et al
PI3Kdelta inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0318.
PubMed Text format Abstract available

VON TRESCKOW J, Cramer P, Bahlo J, Robrecht S, et al
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0313.
PubMed Text format Abstract available

KIVIOJA JL, Thanasopoulou A, Kumar A, Kontro M, et al
Dasatinib and navitoclax act synergistically to target NUP98-NSD1(+)/FLT3-ITD(+) acute myeloid leukemia.
Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0327.
PubMed Text format Abstract available

REEDIJK AMJ, Klein K, Coebergh JWW, Kremer LC, et al
Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality.
Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0314.
PubMed Text format Abstract available

HASAN MK, Rassenti L, Widhopf GF 2nd, Yu J, et al
Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0306.
PubMed Text format Abstract available

CORTES JE, Heidel FH, Hellmann A, Fiedler W, et al
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0312.
PubMed Text format Abstract available

PARK JH, Woo YM, Youm EM, Hamad N, et al
HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia.
Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0321.
PubMed Text format Abstract available

TEN HACKEN E, Gounari M, Ghia P, Burger JA, et al
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0303.
PubMed Text format Abstract available

MODVIG S, Madsen HO, Siitonen SM, Rosthoj S, et al
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
Leukemia. 2018 Dec 14. pii: 10.1038/s41375-018-0307.
PubMed Text format Abstract available

SCHERR M, Kirchhoff H, Battmer K, Wohlan K, et al
Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia.
Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0315.
PubMed Text format Abstract available

ANDERSEN MA, Moser CE, Lundgren J, Niemann CU, et al
Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study.
Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0316.
PubMed Text format Abstract available

ZEIJLEMAKER W, Grob T, Meijer R, Hanekamp D, et al
CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia.
Leukemia. 2018 Dec 12. pii: 10.1038/s41375-018-0326.
PubMed Text format Abstract available

HU X, Xu S, Chen Y, Gao Z, et al
Depletion of Ars2 inhibits cell proliferation and leukemogenesis in acute myeloid leukemia by modulating the miR-6734-3p/p27 axis.
Leukemia. 2018 Dec 5. pii: 10.1038/s41375-018-0301.
PubMed Text format Abstract available

November 2018

BLAGITKO-DORFS N, Schlosser P, Greve G, Pfeifer D, et al
Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation.
Leukemia. 2018 Nov 23. pii: 10.1038/s41375-018-0293.
PubMed Text format Abstract available

October 2018

CAESER R, Collord G, Yao WQ, Chen Z, et al
Targeting MEK in vemurafenib-resistant hairy cell leukemia.
Leukemia. 2018 Oct 19. pii: 10.1038/s41375-018-0270.
PubMed Text format

KRAFT B, Lombard J, Kirsch M, Wuchter P, et al
SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia.
Leukemia. 2018 Oct 15. pii: 10.1038/s41375-018-0287.
PubMed Text format

FRASER G, Cramer P, Demirkan F, Silva RS, et al
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0276.
PubMed Text format Abstract available

OTHUS M, Sekeres MA, Nand S, Garcia-Manero G, et al
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0275.
PubMed Text format Abstract available

OTHUS M, Estey EH, Garcia-Manero G, Wood BL, et al
Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.
Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0274.
PubMed Text format

ROSS DM, Pagani IS, Shanmuganathan N, Kok CH, et al
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0264.
PubMed Text format Abstract available

MANSO BA, Zhang H, Mikkelson MG, Gwin KA, et al
Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients.
Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0280.
PubMed Text format Abstract available

YAN B, Chen Q, Shimada K, Tang M, et al
Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0279.
PubMed Text format Abstract available

WALKER CJ, Oakes CC, Genutis LK, Giacopelli B, et al
Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.
Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0281.
PubMed Text format

BRAESS J, Amler S, Kreuzer KA, Spiekermann K, et al
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0268.
PubMed Text format Abstract available

DOHNER H, Dolnik A, Tang L, Seymour JF, et al
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0257.
PubMed Text format Abstract available

VANDEPOELE K, Van der Meulen J, Denys B
The NF1 hotspot in acute myeloid leukemia: what's in a name?
Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0266.
PubMed Text format

September 2018

BHOJWANI D, Sposto R, Shah NN, Rodriguez V, et al
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
Leukemia. 2018 Sep 28. pii: 10.1038/s41375-018-0265.
PubMed Text format Abstract available

HANNA BS, Roessner PM, Yazdanparast H, Colomer D, et al
Control of chronic lymphocytic leukemia development by clonally-expanded CD8(+) T-cells that undergo functional exhaustion in secondary lymphoid tissues.
Leukemia. 2018 Sep 28. pii: 10.1038/s41375-018-0250.
PubMed Text format Abstract available

MAEKAWA T, Osawa Y, Izumi T, Nagao S, et al
Correction: Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
Leukemia. 2018 Sep 19. pii: 10.1038/s41375-018-0237.
PubMed Text format Abstract available

DEGRYSE S, de Bock CE, Demeyer S, Govaerts I, et al
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Leukemia. 2018 Sep 19. pii: 10.1038/s41375-018-0241.
PubMed Text format Abstract available

PRIETO C, Lopez-Millan B, Roca-Ho H, Stam RW, et al
Correction: NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
Leukemia. 2018 Sep 14. pii: 10.1038/s41375-018-0236.
PubMed Text format Abstract available

KLUPSCH K, Baeriswyl V, Scholz R, Dannenberg J, et al
COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.
Leukemia. 2018 Sep 11. pii: 10.1038/s41375-018-0249.
PubMed Text format

MOUJALLED DM, Pomilio G, Ghiurau C, Ivey A, et al
Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
Leukemia. 2018 Sep 10. pii: 10.1038/s41375-018-0261.
PubMed Text format Abstract available

AGHEL N, Delgado DH, Lipton JH
Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?
Leukemia. 2018 Sep 10. pii: 10.1038/s41375-018-0247.
PubMed Text format Abstract available

August 2018

TAKESHITA A, Asou N, Atsuta Y, Sakura T, et al
Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.
Leukemia. 2018 Aug 9. pii: 10.1038/s41375-018-0233.
PubMed Text format Abstract available

DUPLOYEZ N, Marceau-Renaut A, Villenet C, Petit A, et al
The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
Leukemia. 2018 Aug 8. pii: 10.1038/s41375-018-0227.
PubMed Text format Abstract available

PATNAIK MM, Tefferi A, Garcia-Manero G
Blast-phase chronic myelomonocytic leukemia: more than just semantics.
Leukemia. 2018 Aug 7. pii: 10.1038/s41375-018-0228.
PubMed Text format

KURTZ SE, Eide CA, Kaempf A, Mori M, et al
Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.
Leukemia. 2018 Aug 6. pii: 10.1038/s41375-018-0225.
PubMed Text format

July 2018

LEEKSMA AC, Taylor J, Wu B, Gardner JR, et al
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
Leukemia. 2018 Jul 23. pii: 10.1038/s41375-018-0215.
PubMed Text format Abstract available

KREITMAN RJ, Dearden C, Zinzani PL, Delgado J, et al
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
Leukemia. 2018 Jul 20. pii: 10.1038/s41375-018-0210.
PubMed Text format Abstract available

ALDOSS I, Capelletti M, Park J, Pistofidis RS, et al
Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.
Leukemia. 2018 Jul 19. pii: 10.1038/s41375-018-0213.
PubMed Text format Abstract available

CICCONI L, Fenaux P, Kantarjian H, Tallman M, et al
Molecular remission as a therapeutic objective in acute promyelocytic leukemia.
Leukemia. 2018 Jul 19. pii: 10.1038/s41375-018-0219.
PubMed Text format Abstract available

LI Z, He S, Look AT
The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.
Leukemia. 2018 Jul 15. pii: 10.1038/s41375-018-0201.
PubMed Text format

L'ABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
Leukemia. 2018 Jul 9. pii: 10.1038/s41375-018-0177.
PubMed Text format Abstract available

STUDD JB, Yang M, Li Z, Vijayakrishnan J, et al
Genetic predisposition to B-cell acute lymphoblastic leukemia at 14q11.2 is mediated by a CEBPE promoter polymorphism.
Leukemia. 2018 Jul 6. pii: 10.1038/s41375-018-0184.
PubMed Text format Abstract available

LUNDIN-STROM KB, Biloglav A, Lilljebjorn H, Rissler M, et al
Whole-exome sequencing exploration of acquired uniparental disomies in B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2018 Jul 2. pii: 10.1038/s41375-018-0191.
PubMed Text format

June 2018

VICENTE-DUENAS C, Gonzalez-Herrero I, Sehgal L, Garcia-Ramirez I, et al
Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia.
Leukemia. 2018 Jun 28. pii: 10.1038/s41375-018-0192.
PubMed Text format

MARGOLSKEE E
So-called "blast phase" of chronic myelomonocytic leukemia: a plea for uniform terminology.
Leukemia. 2018 Jun 28. pii: 10.1038/s41375-018-0186.
PubMed Text format

BOND J, Labis E, Marceau-Renaut A, Duployez N, et al
Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia.
Leukemia. 2018 Jun 27. pii: 10.1038/s41375-018-0187.
PubMed Text format

HOLMQVIST AS, Chen Y, Wu J, Kung M, et al
Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2.
Leukemia. 2018 Jun 26. pii: 10.1038/s41375-018-0171.
PubMed Text format

CRIADO I, Blanco E, Rodriguez-Caballero A, Alcoceba M, et al
Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia.
Leukemia. 2018 Jun 21. pii: 10.1038/s41375-018-0164.
PubMed Text format

SUTTORP M, Schulze P, Glauche I, Gohring G, et al
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
Leukemia. 2018 Jun 20. pii: 10.1038/s41375-018-0179.
PubMed Text format Abstract available

GEBHARD C, Glatz D, Schwarzfischer L, Wimmer J, et al
Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association.
Leukemia. 2018 Jun 20. pii: 10.1038/s41375-018-0165.
PubMed Text format Abstract available

ERNST T, Busch M, Rinke J, Ernst J, et al
Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia.
Leukemia. 2018 Jun 13. pii: 10.1038/s41375-018-0157.
PubMed Text format

BODDU P, Gurguis C, Sanford D, Cortes J, et al
Response kinetics and factors predicting survival in core-binding factor leukemia.
Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0158.
PubMed Text format

BOUDREAUX SP, Duren RP, Call SG, Nguyen L, et al
Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.
Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0174.
PubMed Text format Abstract available

TASIAN SK, Casas JA, Posocco D, Gandre-Babbe S, et al
Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0169.
PubMed Text format Abstract available

TIMILSHINA N, Breunis H, Tomlinson GA, Brandwein JM, et al
Long-term recovery of quality of life and physical function over three years in adult survivors of acute myeloid leukemia after intensive chemotherapy.
Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0162.
PubMed Text format Abstract available

BARGHOUT SH, Patel PS, Wang X, Xu GW, et al
Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.
Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0167.
PubMed Text format Abstract available

EISFELD AK, Kohlschmidt J, Mrozek K, Mims A, et al
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.
Leukemia. 2018 Jun 5. pii: 10.1038/s41375-018-0147.
PubMed Text format Abstract available

DONG X, Zhang W, Wu H, Huang J, et al
Structural basis of DUX4/IGH-driven transactivation.
Leukemia. 2018;32:1466-1476.
PubMed Text format Abstract available

INOUE D, Fujino T, Sheridan P, Zhang YZ, et al
A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies.
Leukemia. 2018;32:1327-1337.
PubMed Text format Abstract available

VERBIEST T, Finnon R, Brown N, Cruz-Garcia L, et al
Tracking preleukemic cells in vivo to reveal the sequence of molecular events in radiation leukemogenesis.
Leukemia. 2018;32:1435-1444.
PubMed Text format Abstract available

ZHENG L, Xu L, Xu Q, Yu L, et al
Utx loss causes myeloid transformation.
Leukemia. 2018;32:1458-1465.
PubMed Text format Abstract available

May 2018

CHEUNG LC, Tickner J, Hughes AM, Skut P, et al
New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.
Leukemia. 2018 May 8. pii: 10.1038/s41375-018-0144.
PubMed Text format Abstract available

MEGGENDORFER M, Cappelli LV, Walter W, Haferlach C, et al
IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies.
Leukemia. 2018;32:1249-1253.
PubMed Text format

DAVIDSSON J, Puschmann A, Tedgard U, Bryder D, et al
SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies.
Leukemia. 2018;32:1106-1115.
PubMed Text format Abstract available

ZHENG W, O'Hear CE, Alli R, Basham JH, et al
PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.
Leukemia. 2018;32:1157-1167.
PubMed Text format Abstract available

JETANI H, Garcia-Cadenas I, Nerreter T, Thomas S, et al
CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib.
Leukemia. 2018;32:1168-1179.
PubMed Text format Abstract available

ZAMPINI M, Tregnago C, Bisio V, Simula L, et al
Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML.
Leukemia. 2018;32:1124-1134.
PubMed Text format Abstract available

WONG ACH, Rasko JEJ, Wong JJ
We skip to work: alternative splicing in normal and malignant myelopoiesis.
Leukemia. 2018;32:1081-1093.
PubMed Text format Abstract available

TEFFERI A, Mudireddy M, Mannelli F, Begna KH, et al
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.
Leukemia. 2018;32:1200-1210.
PubMed Text format Abstract available

April 2018

PATNAIK MM, Pierola AA, Vallapureddy R, Yalniz FF, et al
Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases.
Leukemia. 2018 Apr 25. pii: 10.1038/s41375-018-0143.
PubMed Text format

HUITING LN, Samaha Y, Zhang GL, Roderick JE, et al
UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response.
Leukemia. 2018 Apr 25. pii: 10.1038/s41375-018-0141.
PubMed Text format Abstract available

XIAO W, Rampal R, Zhang Y, Cimera R, et al
JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.
Leukemia. 2018 Apr 24. pii: 10.1038/s41375-018-0145.
PubMed Text format

KAYSER S, Schlenk RF, Platzbecker U
Management of patients with acute promyelocytic leukemia.
Leukemia. 2018 Apr 24. pii: 10.1038/s41375-018-0139.
PubMed Text format Abstract available

GARCIA EG, Iyer S, Garcia SP, Loontiens S, et al
Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia.
Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0130.
PubMed Text format

RENNEVILLE A, Attias P, Thomas X, Bally C, et al
Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.
Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0137.
PubMed Text format

DE BIE J, Demeyer S, Alberti-Servera L, Geerdens E, et al
Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia.
Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0127.
PubMed Text format Abstract available

PASCHKA P, Schlenk RF, Weber D, Benner A, et al
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
Leukemia. 2018 Apr 17. pii: 10.1038/s41375-018-0129.
PubMed Text format Abstract available

STUDENCKA-TURSKI M, Maubach G, Feige MH, Naumann M, et al
Constitutive activation of nuclear factor kappa B-inducing kinase counteracts apoptosis in cells with rearranged mixed lineage leukemia gene.
Leukemia. 2018 Apr 17. pii: 10.1038/s41375-018-0128.
PubMed Text format

WARTIOVAARA-KAUTTO U, Hirvonen EAM, Pitkanen E, Heckman C, et al
Germline alterations in a consecutive series of acute myeloid leukemia.
Leukemia. 2018 Apr 10. pii: 10.1038/s41375-018-0049.
PubMed Text format

CASADO P, Wilkes EH, Miraki-Moud F, Hadi MM, et al
Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.
Leukemia. 2018 Apr 7. pii: 10.1038/s41375-018-0032.
PubMed Text format

HU T, Wu Q, Chong Y, Qin H, et al
FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0124.
PubMed Text format Abstract available

PATNAIK MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, et al
A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.
Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0121.
PubMed Text format

PETER B, Bibi S, Eisenwort G, Wingelhofer B, et al
Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
Leukemia. 2018;32:1016-1022.
PubMed Text format Abstract available

MAURA F, Petljak M, Lionetti M, Cifola I, et al
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines.
Leukemia. 2018;32:1044-1048.
PubMed Text format

SANARICO AG, Ronchini C, Croce A, Memmi EM, et al
The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia.
Leukemia. 2018;32:911-919.
PubMed Text format Abstract available

MARSILIO S, Khiabanian H, Fabbri G, Vergani S, et al
Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.
Leukemia. 2018;32:1041-1044.
PubMed Text format

March 2018

HOSSEINI MM, Kurtz SE, Abdelhamed S, Mahmood S, et al
Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
Leukemia. 2018 Mar 29. pii: 10.1038/s41375-018-0112.
PubMed Text format Abstract available

THAN H, Qiao Y, Huang X, Yan D, et al
Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.
Leukemia. 2018 Mar 27. pii: 10.1038/s41375-018-0050.
PubMed Text format

HOJJAT-FARSANGI M, Daneshmanesh AH, Khan AS, Shetye J, et al
First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.
Leukemia. 2018 Mar 27. pii: 10.1038/s41375-018-0113.
PubMed Text format

THI NGOC PC, Tan SH, Tan TK, Chan MM, et al
Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia.
Leukemia. 2018 Mar 26. pii: 10.1038/s41375-018-0110.
PubMed Text format Abstract available

GHIA P, Rawstron A
Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.
Leukemia. 2018 Mar 26. pii: 10.1038/s41375-018-0109.
PubMed Text format Abstract available

KUCHENBAUER F, Buske C
Revisiting thrombocytopenia in acute promyelocytic leukemia.
Leukemia. 2018 Mar 23. pii: 10.1038/s41375-018-0105.
PubMed Text format

RUDAT S, Pfaus A, Cheng YY, Holtmann J, et al
RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.
Leukemia. 2018 Mar 22. pii: 10.1038/s41375-018-0102.
PubMed Text format Abstract available

GENTILE M, Shanafelt TD, Reda G, Mauro FR, et al
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
Leukemia. 2018 Mar 20. pii: 10.1038/s41375-018-0100.
PubMed Text format

BURNS MA, Liao ZW, Yamagata N, Pouliot GP, et al
Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.
Leukemia. 2018 Mar 20. pii: 10.1038/s41375-018-0097.
PubMed Text format Abstract available

SUN W, Malvar J, Sposto R, Verma A, et al
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
Leukemia. 2018 Mar 15. pii: 10.1038/s41375-018-0094.
PubMed Text format Abstract available

QIN YZ, Huang XJ, Zhu HH
Identification of a novel CPSF6-RARG fusion transcript in acute myeloid leukemia resembling acute promyelocytic leukemia.
Leukemia. 2018 Mar 14. pii: 10.1038/s41375-018-0095.
PubMed Text format

GUNNARSSON R, Dilorenzo S, Lundin-Strom KB, Olsson L, et al
Mutation, methylation, and gene expression profiles in dup(1q)-positive pediatric B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2018 Mar 12. pii: 10.1038/s41375-018-0092.
PubMed Text format Abstract available

KELLY AD, Madzo J, Madireddi P, Kropf P, et al
Demethylator phenotypes in acute myeloid leukemia.
Leukemia. 2018 Mar 7. pii: 10.1038/s41375-018-0084.
PubMed Text format Abstract available

GERBOTH S, Frittoli E, Palamidessi A, Baltanas FC, et al
Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
Leukemia. 2018;32:820-827.
PubMed Text format Abstract available

ANDERSSON EI, Putzer S, Yadav B, Dufva O, et al
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Leukemia. 2018;32:774-787.
PubMed Text format Abstract available

February 2018

TAWANA K, Drazer MW, Churpek JE
Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?
Leukemia. 2018 Feb 27. pii: 10.1038/s41375-018-0051.
PubMed Text format Abstract available

MARUFFI M, Sposto R, Oberley MJ, Kysh L, et al
Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis.
Leukemia. 2018 Feb 27. pii: 10.1038/s41375-018-0058.
PubMed Text format Abstract available

SAUSSELE S, Hehlmann R, Fabarius A, Jeromin S, et al
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.
Leukemia. 2018 Feb 26. pii: 10.1038/s41375-018-0055.
PubMed Text format Abstract available

ALI A, Penneroux J, Dal Bello R Jr, Masse A, et al
Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.
Leukemia. 2018 Feb 26. pii: 10.1038/s41375-018-0076.
PubMed Text format

PETROV JC, Wada M, Pinz KG, Yan LE, et al
Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia.
Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0075.
PubMed Text format Abstract available

HNIZDA A, Fabry M, Moriyama T, Pachl P, et al
Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.
Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0073.
PubMed Text format Abstract available

EISFELD AK, Kohlschmidt J, Mrozek K, Blachly JS, et al
Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.
Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0068.
PubMed Text format Abstract available

BICCLER JL, Ostgard LSG, Severinsen MT, Marcher CW, et al
Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study.
Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0054.
PubMed Text format

ROTHENBERG-THURLEY M, Amler S, Goerlich D, Kohnke T, et al
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0034.
PubMed Text format Abstract available

GUPTA S, Devidas M, Loh ML, Raetz EA, et al
Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).
Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0039.
PubMed Text format Abstract available

FONTANA MC, Marconi G, Feenstra JDM, Fonzi E, et al
Chromothripsis in acute myeloid leukemia: biological features and impact on survival.
Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0035.
PubMed Text format Abstract available

LAVALLEE VP, Chagraoui J, MacRae T, Marquis M, et al
Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin.
Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0069.
PubMed Text format Abstract available

DAVER N, Boddu P, Garcia-Manero G, Yadav SS, et al
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0070.
PubMed Text format Abstract available

L ABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0033.
PubMed Text format Abstract available

RASCHE M, Zimmermann M, Borschel L, Bourquin JP, et al
Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.
Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0071.
PubMed Text format Abstract available

STRATI P, Ferrajoli A, Wierda WG, Jain N, et al
Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
Leukemia. 2018 Feb 20. pii: 10.1038/s41375-018-0059.
PubMed Text format

CRAMER SD, Hixon JA, Andrews C, Porter RJ, et al
Mutant IL-7Ralpha and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia.
Leukemia. 2018 Feb 15. pii: 10.1038/s41375-017-0001.
PubMed Text format

SUAREZ-GONZALEZ J, Martinez-Laperche C, Martinez N, Rodriguez-Macias G, et al
Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis.
Leukemia. 2018 Feb 5. pii: 10.1038/s41375-018-0042.
PubMed Text format

PENG D, Wang H, Li L, Ma X, et al
miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding.
Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0015.
PubMed Text format Abstract available

LA STARZA R, Messina M, Gianfelici V, Pierini V, et al
High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement.
Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0031.
PubMed Text format

WINGELHOFER B, Maurer B, Heyes EC, Cumaraswamy AA, et al
Pharmacologic inhibition of STAT5 in acute myeloid leukemia.
Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0005.
PubMed Text format Abstract available

MALCIKOVA J, Tausch E, Rossi D, Sutton LA, et al
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.
Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0007.
PubMed Text format Abstract available

BALASUBRAMANIAN SK, Aly M, Nagata Y, Bat T, et al
Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.
Leukemia. 2018;32:550-553.
PubMed Text format

KLYMENKO T, Bloehdorn J, Bahlo J, Robrecht S, et al
Lamin B1 regulates somatic mutations and progression of B-cell malignancies.
Leukemia. 2018;32:364-375.
PubMed Text format Abstract available

STENGEL A, Kern W, Meggendorfer M, Nadarajah N, et al
Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.
Leukemia. 2018;32:295-302.
PubMed Text format Abstract available

KUBESOVA B, Pavlova S, Malcikova J, Kabathova J, et al
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
Leukemia. 2018;32:450-461.
PubMed Text format Abstract available

DEANGELO DJ, George TI, Linder A, Langford C, et al
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
Leukemia. 2018;32:470-478.
PubMed Text format Abstract available

LIU E, Tong Y, Dotti G, Shaim H, et al
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
Leukemia. 2018;32:520-531.
PubMed Text format Abstract available

MEYER C, Burmeister T, Groger D, Tsaur G, et al
The MLL recombinome of acute leukemias in 2017.
Leukemia. 2018;32:273-284.
PubMed Text format Abstract available

GARRIDO CASTRO P, van Roon EHJ, Pinhancos SS, Trentin L, et al
The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
Leukemia. 2018;32:323-331.
PubMed Text format Abstract available

KAUSHIK S, Liu F, Veazey KJ, Gao G, et al
Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Leukemia. 2018;32:499-509.
PubMed Text format Abstract available

January 2018

SUN X, Ren Y, Gunawan S, Teng P, et al
Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099.
Leukemia. 2018 Jan 30. pii: 10.1038/s41375-018-0020.
PubMed Text format

JO S, Lee JH, Mattei JJ, Barrett DM, et al
Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.
Leukemia. 2018 Jan 5. pii: leu2017312. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

PIETTE C, Suciu S, Clappier E, Bertrand Y, et al
Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials.
Leukemia. 2018;32:244-248.
PubMed Text format

BUONTEMPO F, McCubrey JA, Orsini E, Ruzzene M, et al
Therapeutic targeting of CK2 in acute and chronic leukemias.
Leukemia. 2018;32:1-10.
PubMed Text format Abstract available

BRAZDILOVA K, Plevova K, Skuhrova Francova H, Kockova H, et al
Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL.
Leukemia. 2018;32:234-236.
PubMed Text format

BODDU P, Jorgensen J, Kantarjian H, Borthakur G, et al
Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.
Leukemia. 2018;32:241-244.
PubMed Text format

GU S, Sayad A, Chan G, Yang W, et al
SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
Leukemia. 2018;32:203-213.
PubMed Text format Abstract available

MINGAY M, Chaturvedi A, Bilenky M, Cao Q, et al
Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia.
Leukemia. 2018;32:11-20.
PubMed Text format Abstract available

GOLE B, Mian E, Rall M, Wiesmuller L, et al
Base excision repair proteins couple activation-induced cytidine deaminase and endonuclease G during replication stress-induced MLL destabilization.
Leukemia. 2018;32:159-167.
PubMed Text format Abstract available

BROWN JR, Hillmen P, O'Brien S, Barrientos JC, et al
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
Leukemia. 2018;32:83-91.
PubMed Text format Abstract available

VILLARESE P, Lours C, Trinquand A, Le Noir S, et al
TCRalpha rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome.
Leukemia. 2018;32:61-71.
PubMed Text format Abstract available

SUN L, Shi Y, Wang G, Wang X, et al
PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells.
Leukemia. 2018;32:184-193.
PubMed Text format Abstract available

WELSH SJ, Churchman ML, Togni M, Mullighan CG, et al
Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
Leukemia. 2018;32:38-48.
PubMed Text format Abstract available

December 2017

GUPTA S, Devidas M, Loh ML, Raetz EA, et al
Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG).
Leukemia. 2017 Dec 18. pii: leu2017341. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

BU J, Chen A, Yan X, He F, et al
SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.
Leukemia. 2017 Dec 18. pii: leu2017339. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

FONTANA MC, Marconi G, Feenstra JDM, Fonzi E, et al
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival.
Leukemia. 2017 Dec 18. pii: leu2017351. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

ROTHENBERG-THURLEY M, Amler S, Goerlich D, Kohnke T, et al
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
Leukemia. 2017 Dec 18. pii: leu2017350. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

CASADO P, Wilkes EH, Miraki-Moud F, Hadi MM, et al
Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.
Leukemia. 2017 Dec 12. pii: leu2017349. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

TIRADO-GONZALEZ I, Czlonka E, Nevmerzhitskaya A, Soetopo D, et al
CRISPR/Cas9 edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC.
Leukemia. 2017 Dec 6. pii: leu2017346. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

DRIESSEN EMC, de Lorenzo P, Campbell M, Felice M, et al
Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.
Leukemia. 2017;31:2854.
PubMed Text format Abstract available

GRZES KM, Swamy M, Hukelmann JL, Emslie E, et al
Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy.
Leukemia. 2017;31:2771-2779.
PubMed Text format Abstract available

GARCIA-MANERO G, Sekeres MA, Egyed M, Breccia M, et al
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts.
Leukemia. 2017;31:2799-2806.
PubMed Text format Abstract available

TESIO M, Trinquand A, Ballerini P, Hypolite G, et al
Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia.
Leukemia. 2017;31:2594-2600.
PubMed Text format Abstract available

ELDER A, Bomken S, Wilson I, Blair HJ, et al
Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia.
Leukemia. 2017;31:2577-2586.
PubMed Text format Abstract available

DELGADO-MARTIN C, Meyer LK, Huang BJ, Shimano KA, et al
JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
Leukemia. 2017;31:2568-2576.
PubMed Text format Abstract available

RASCHE M, von Neuhoff C, Dworzak M, Bourquin JP, et al
Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004.
Leukemia. 2017;31:2807-2814.
PubMed Text format Abstract available

ZHANG H, Reister Schultz A, Luty S, Rofelty A, et al
Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations.
Leukemia. 2017;31:2752-2760.
PubMed Text format Abstract available

LYU Y, Lou J, Yang Y, Feng J, et al
Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.
Leukemia. 2017;31:2543-2551.
PubMed Text format Abstract available

YOKOTA A, Hirai H, Shoji T, Maekawa T, et al
Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo.
Leukemia. 2017;31:2742-2751.
PubMed Text format Abstract available

November 2017

LABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences.
Leukemia. 2017 Nov 28. pii: leu2017337. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

NIMMAGADDA SC, Frey S, Edelmann B, Hellmich C, et al
Bruton's Tyrosine Kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.
Leukemia. 2017 Nov 7. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

LHERMITTE L, Mejstrikova E, van der Sluijs-Gelling AJ, Grigore GE, et al
Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia.
Leukemia. 2017 Nov 1. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

WALF-VORDERWULBECKE V, Pearce K, Brooks T, Hubank M, et al
Targeting acute myeloid leukemia by drug-induced c-MYB degradation.
Leukemia. 2017 Nov 1. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

HADZIJUSUFOVIC E, Albrecht-Schgoer K, Huber K, Hoermann G, et al
Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.
Leukemia. 2017;31:2388-2397.
PubMed Text format Abstract available

PULIKKAN JA, Tenen DG, Behre G
C/EBPalpha deregulation as a paradigm for leukemogenesis.
Leukemia. 2017;31:2279-2285.
PubMed Text format Abstract available

LIU X, Rothe K, Yen R, Fruhstorfer C, et al
A novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy.
Leukemia. 2017;31:2376-2387.
PubMed Text format Abstract available

THIEL VN, Giaimo BD, Schwarz P, Soller K, et al
Heterodimerization of AML1/ETO with CBFbeta is required for leukemogenesis but not for myeloproliferation.
Leukemia. 2017;31:2491-2502.
PubMed Text format Abstract available

O'LEARY HA, Capitano M, Cooper S, Mantel C, et al
DPP4 truncated GM-CSF and IL-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms.
Leukemia. 2017;31:2468-2478.
PubMed Text format Abstract available

HOWARD DR, Munir T, McParland L, Rawstron AC, et al
Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.
Leukemia. 2017;31:2416-2425.
PubMed Text format Abstract available

SAVINO AM, Sarno J, Trentin L, Vieri M, et al
The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.
Leukemia. 2017;31:2365-2375.
PubMed Text format Abstract available

KRAMER AC, Kothari A, Wilson WC, Celik H, et al
Dnmt3a regulates T-cell development and suppresses T-ALL transformation.
Leukemia. 2017;31:2479-2490.
PubMed Text format Abstract available

ABRAHAM M, Klein S, Bulvik B, Wald H, et al
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
Leukemia. 2017;31:2336-2346.
PubMed Text format Abstract available

HA VL, Luong A, Li F, Casero D, et al
The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation.
Leukemia. 2017;31:2503-2514.
PubMed Text format Abstract available

DELL'AVERSANA C, Giorgio C, D'Amato L, Lania G, et al
miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.
Leukemia. 2017;31:2315-2325.
PubMed Text format Abstract available

October 2017

SAID B, Gilles S, Weisdorf D, Rashidi A, et al
The role of bone marrow morphology in the diagnosis of relapsed acute myeloid leukemia.
Leukemia. 2017 Oct 31. doi: 10.1038/leu.2017.
PubMed Text format

YAN F, Shen N, Pang JX, Zhao N, et al
A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target.
Leukemia. 2017 Oct 10. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

TOPP MS, Stelljes M, Zugmaier G, Barnette P, et al
Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.
Leukemia. 2017 Oct 9. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

JERCHEL IS, Hoogkamer AQ, Aries IM, Steeghs EMP, et al
RAS pathway mutations as predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2017 Oct 3. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

LI Z, Abraham BJ, Berezovskaya A, Farah N, et al
APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
Leukemia. 2017;31:2057-2064.
PubMed Text format Abstract available

MUNIR T, Howard DR, McParland L, Pocock C, et al
Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
Leukemia. 2017;31:2085-2093.
PubMed Text format Abstract available

JU HQ, Zhan G, Huang A, Sun Y, et al
ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
Leukemia. 2017;31:2143-2150.
PubMed Text format Abstract available

DUELL J, Dittrich M, Bedke T, Mueller T, et al
Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.
Leukemia. 2017;31:2181-2190.
PubMed Text format Abstract available

CHEN KH, Wada M, Pinz KG, Liu H, et al
Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
Leukemia. 2017;31:2151-2160.
PubMed Text format Abstract available

September 2017

FUJITA S, Honma D, Adachi N, Araki K, et al
Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
Leukemia. 2017 Sep 27. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

PRIETO C, Lopez-Millan B, Roca-Ho H, Stam RW, et al
NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
Leukemia. 2017 Sep 25. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

BENEDETTI D, Tissino E, Pozzo F, Bittolo T, et al
NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: Link between the NOTCH1 and the NF-kB pathways.
Leukemia. 2017 Sep 22. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

JO S, Lee JH, Mattei JJ, Barrett DM, et al
Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.
Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

DEL GIUDICE I, Rigolin GM, Raponi S, Cafforio L, et al
Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low and very-low risk genetic profile.
Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

NADEU F, Clot G, Delgado J, Martin-Garcia D, et al
Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.
Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

HOSPITAL MA, Jacquel A, Mazed F, Saland E, et al
RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

SAKURA T, Hayakawa F, Sugiura I, Murayama T, et al
High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG.
Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

WAIBEL M, Vervoort SJ, Kong IY, Heinzel S, et al
Epigenetic targeting of Notch1 driven transcription using the HDACi panobinostat is a potential therapy against T cell acute lymphoblastic leukemia.
Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

TAKAO S, Chien W, Madan V, Lin DC, et al
Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia.
Leukemia. 2017 Sep 14. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

MARNETH AE, Prange KHM, Al Hinai ASA, Bergevoet SM, et al
C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.
Leukemia. 2017 Sep 5. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

RINKE J, Muller JP, Blaess MF, Chase A, et al
Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.
Leukemia. 2017;31:1936-1943.
PubMed Text format Abstract available

KIM T, Tyndel MS, Kim HJ, Ahn JS, et al
The clonal origins of leukemic progression of myelodysplasia.
Leukemia. 2017;31:1928-1935.
PubMed Text format Abstract available

SAENZ DT, Fiskus W, Qian Y, Manshouri T, et al
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
Leukemia. 2017;31:1951-1961.
PubMed Text format Abstract available

RONCHINI C, Brozzi A, Riva L, Luzi L, et al
PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias.
Leukemia. 2017;31:1975-1986.
PubMed Text format Abstract available

August 2017

DEGRYSE S, de Bock CE, Demeyer S, Govaerts I, et al
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Leukemia. 2017 Aug 30. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

JYOTSANA N, Sharma A, Chaturvedi A, Scherr M, et al
RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo.
Leukemia. 2017 Aug 22. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

ZHAO L, Alkadi H, Kwon EM, Zhen T, et al
The C-terminal multimerization domain is essential for leukemia development by CBFbeta-SMMHC in a mouse knockin model.
Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

TOFT N, Birgens H, Abrahamsson J, Griskevicius L, et al
Results of NOPHO ALL2008 treatment for patients 1-45 years with acute lymphoblastic leukemia.
Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

PENA-MARTINEZ P, Eriksson M, Ramakrishnan R, Chapellier M, et al
Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6 dependent manner.
Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

KUMAR B, Garcia M, Weng L, Jung X, et al
Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.
Leukemia. 2017 Aug 17. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

ARTESI M, Marcais A, Durkin K, Rosewick N, et al
Monitoring molecular response in adult t-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality.
Leukemia. 2017 Aug 16. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

HOECHSTETTER MA, Busch R, Eichhorst B, Buhler A, et al
Early, risk-adapted treatment with fludarabine in binet stage a chronic lymphocytic leukemia patients: Results of the CLL1 trial of the German CLL study group.
Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

HEHLMANN R, Lauseker M, Saussele S, Pfirrmann M, et al
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

REITER K, Polzer H, Krupka C, Maiser A, et al
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

MASCIARELLI S, Capuano E, Ottone T, Divona M, et al
'Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress'.
Leukemia. 2017 Aug 4. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

RAFIQ S, Purdon TJ, Daniyan AF, Koneru M, et al
Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.
Leukemia. 2017;31:1788-1797.
PubMed Text format Abstract available

DRENNAN S, D'Avola A, Gao Y, Weigel C, et al
IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.
Leukemia. 2017;31:1686-1694.
PubMed Text format Abstract available

July 2017

KIM HG, LeGrand J, Swindle CS, Nick HJ, et al
The assembly competence domain is essential for inv(16)-associated acute myeloid leukemia.
Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

YIGIT B, Wang N, Chen SS, Chiorazzi N, et al
Inhibition of Reactive oxygen species (ROS) limits expansion of chronic lymphocytic leukemia cells.
Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

TEH TC, Nguyen NY, Moujalled DM, Segal D, et al
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

GIRARDI T, Vereecke S, Sulima SO, Khan Y, et al
The T-cell leukemia associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

XIA F, Zhang Y, Xie L, Jiang H, et al
B7-H4 enhances the differentiation of murine leukemia-initiating cells via the PTEN/AKT/RCOR2/RUNX1 pathways.
Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

SOPPER S, Mustjoki S, Gjertsen BT, Giles F, et al
NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib.
Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

AL-SAWAF O, Robrecht S, Bahlo J, Fink AM, et al
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.
Leukemia. 2017 Jul 12. doi: 10.1038/leu.2017.
PubMed Text format

BECK D, Thoms JAI, Palu C, Herold T, et al
A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.
Leukemia. 2017 Jul 4. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

HOURIGAN CS, Gale RP, Gormley NJ, Ossenkoppele GJ, et al
Measurable residual disease testing in acute myeloid leukaemia.
Leukemia. 2017;31:1482-1490.
PubMed Text format Abstract available

CUTLER JA, Tahir R, Sreenivasamurthy SK, Mitchell C, et al
Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.
Leukemia. 2017;31:1513-1524.
PubMed Text format Abstract available

RIBEIRO ST, Tesio M, Ribot JC, Macintyre E, et al
Casein kinase 2 controls the survival of normal thymic and leukemic gammadelta T cells via promotion of AKT signaling.
Leukemia. 2017;31:1603-1610.
PubMed Text format Abstract available

June 2017

ANGENENDT L, Reuter S, Kentrup D, Benk AS, et al
An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.
Leukemia. 2017 Jun 30. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

YABE T, Azuma F, Kashiwase K, Matsumoto K, et al
HLA-DPB1 mismatch induces a graft-versus-leukemia (GVL) effect without severe acute GVHD after single-unit umbilical cord blood transplantation.
Leukemia. 2017 Jun 27. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

TIAO G, Improgo MR, Kasar S, Poh W, et al
Rare germline variants in ATM are associated with chronic lymphocytic leukemia.
Leukemia. 2017 Jun 27. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

GAIDZIK VI, Weber D, Paschka P, Kaumanns A, et al
DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
Leukemia. 2017 Jun 23. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

ZHANG Q, Ball MC, Zhao Y, Balasis M, et al
Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.
Leukemia. 2017 Jun 21. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

RIO-MACHIN A, Gomez-Lopez G, Munoz J, Garcia-Martinez F, et al
The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia.
Leukemia. 2017 Jun 20. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

GODWIN CD, Gale RP, Walter RB
Gemtuzumab ozogamicin in acute myeloid leukemia.
Leukemia. 2017 Jun 13. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

SANTINI V, Allione B, Zini G, Gioia D, et al
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
Leukemia. 2017 Jun 13. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

BURNS A, Alsolami R, Becq J, Timbs A, et al
Whole genome sequencing of chronic lymphocytic leukemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.
Leukemia. 2017 Jun 6. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

MARTINEZ-CUADRON D, Montesinos P, Vellenga E, Bernal T, et al
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.
Leukemia. 2017 Jun 6. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

PROMOD ST, Johnson DP, Bennett SE, Dennis EM, et al
HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
Leukemia. 2017 Jun 5. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

HAHN M, Burckert JP, Luttenberger CA, Klebow S, et al
Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-kappaB signaling.
Leukemia. 2017 Jun 1. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

USTUN C, Giannotti F, Zhang MJ, Wang HL, et al
Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.
Leukemia. 2017;31:1408-1414.
PubMed Text format Abstract available

HERNDON TM, Chen SS, Saba NS, Valdez J, et al
Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.
Leukemia. 2017;31:1340-1347.
PubMed Text format Abstract available

YAN F, Shen N, Pang JX, Zhang YW, et al
Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells.
Leukemia. 2017;31:1434-1442.
PubMed Text format Abstract available

CHENG G, Liu F, Asai T, Lai F, et al
Loss of p300 accelerates MDS-associated leukemogenesis.
Leukemia. 2017;31:1382-1390.
PubMed Text format Abstract available

RODMAN C, Almeida-Porada G, George SK, Moon J, et al
In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells.
Leukemia. 2017;31:1398-1407.
PubMed Text format Abstract available

CARTER MJ, Cox KL, Blakemore SJ, Turaj AH, et al
PI3Kdelta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.
Leukemia. 2017;31:1423-1433.
PubMed Text format Abstract available

May 2017

HALPERN AB, Othus M, Huebner EM, Buckley SA, et al
Mitoxantrone, etoposide, and cytarabine (MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: A phase 1/2 study.
Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

HA JS, Do YR, Ki CS, Lee C, et al
Identification of a novel PML-RARG fusion in acute promyelocytic leukemia.
Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

PATEL B, Przychodzen B, Thota S, Radivoyevitch T, et al
Genomic determinants of chronic myelomonocytic leukemia.
Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

HEILMANN AM, Schrock AB, He J, Nahas M, et al
Novel PDGFRB fusions in childhood B and T acute lymphoblastic leukemia.
Leukemia. 2017 May 29. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

MA Z, Zhao X, Huang J, Jia X, et al
A critical role of periostin in B-cell acute lymphoblastic leukemia.
Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

BERNSON E, Hallner A, Sander FE, Wilsson O, et al
Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

HINZE L, Moricke A, Zimmermann M, Junk S, et al
Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

CHEN L, Mao H, Zhang J, Chu J, et al
Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.
Leukemia. 2017 May 12. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

PAN J, Yang J, Deng B, Zhao X, et al
High efficacy and safety of low dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
Leukemia. 2017 May 11. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

ROSSETTI C, Picardi E, Ye M, Camilli G, et al
RNA editing signature during myeloid leukemia cell differentiation.
Leukemia. 2017 May 9. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

HASAN K, Yu J, Chen L, Cui B, et al
Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
Leukemia. 2017 May 3. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

YU J, Chen L, Chen Y, Hasan K, et al
Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.
Leukemia. 2017 May 3. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

SLINGER E, Thijssen R, Kater AP, Eldering E, et al
Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

LONG J, Fang WY, Chang L, Gao WH, et al
Targeting HDAC3, new partner protein of AKT in the reversal of chemo-resistance in acute myeloid leukemia via DNA damage response.
Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

GUNNARSSON N, Hoglund M, Stenke L, Sandin F, et al
No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia-a population-based study in Sweden.
Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

EIRING AM, Page BDG, Kraft IL, Mason CC, et al
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Leukemia. 2017;31:1253-1254.
PubMed Text format

LEROY E, Constantinescu SN
Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition.
Leukemia. 2017;31:1023-1038.
PubMed Text format Abstract available

KAZIANKA L, Drucker C, Skrabs C, Thomas W, et al
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Leukemia. 2017;31:1117-1122.
PubMed Text format Abstract available

MALANI D, Murumagi A, Yadav B, Kontro M, et al
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
Leukemia. 2017;31:1187-1195.
PubMed Text format Abstract available

LIU TH, Tang YJ, Huang Y, Wang L, et al
Expression of the fetal hematopoiesis regulator FEV indicates leukemias of prenatal origin.
Leukemia. 2017;31:1079-1086.
PubMed Text format Abstract available

April 2017

CAZZANIGA G, Bisanti L, Randi G, Deandrea S, et al
Possible role of pandemic AH1N1 swine flu virus in a childhood leukemia cluster.
Leukemia. 2017 Apr 27. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

ROSENQUIST R, Ghia P, Hadzidimitriou A, Sutton LA, et al
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: Updated eric recommendations.
Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

MAEKAWA T, Osawa Y, Izumi T, Nagao S, et al
Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

KONGTIM P, Adekola K, Milton DR, Ramlal R, et al
Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Leukemia. 2017 Apr 12. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

HAN SH, Kim SH, Kim HJ, Lee Y, et al
Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.
Leukemia. 2017 Apr 11. doi: 10.1038/leu.2017.
PubMed Text format

JONES D, Woyach JA, Zhao W, Caruthers S, et al
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

SILVA P, Neumann M, Schroeder MP, Vosberg S, et al
Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.
Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

HEATH EM, Chan SM, Minden MD, Murphy T, et al
Biological and clinical consequences of NPM1 mutations in AML.
Leukemia. 2017;31:798-807.
PubMed Text format Abstract available

VALENT P, Sotlar K, Blatt K, Hartmann K, et al
Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.
Leukemia. 2017;31:788-797.
PubMed Text format Abstract available

SCHUTZ C, Inselmann S, Sausslele S, Dietz CT, et al
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
Leukemia. 2017;31:829-836.
PubMed Text format Abstract available

March 2017

HEROLD S, Kuhn M, Bonin MV, Stange T, et al
Donor cell leukemia-Evidence for multiple pre-leukemic clones and parallel long term clonal evolution in donor and recipient.
Leukemia. 2017 Mar 28. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

ANADON C, van Tetering G, Ferreira HJ, Moutinho C, et al
Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia.
Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

COSSON A, Chapiro E, Bougacha N, Lambert J, et al
Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: Analysis of the central role of XPO1.
Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

MONTALBAN-BRAVO G, Huang X, Naqvi K, Jabbour E, et al
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
PubMed Text format

WALKER CJ, Eisfeld AK, Genutis LK, Bainazar M, et al
No evidence for microsatellite instability in acute myeloid leukemia.
Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

KAYSER S, Krzykalla J, Elliott MA, Norsworthy K, et al
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

ZHOU H, Mak PY, Mu H, Mak DH, et al
Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

EISFELD AK, Mrozek K, Kohlschmidt J, Nicolet D, et al
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.
Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

POZZO F, Bittolo T, Vendramini E, Bomben R, et al
NOTCH1 mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin-1 and ribosome associated components.
Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
PubMed Text format Abstract available

KOEFFLER HP, Leong G
Preleukemia: one name, many meanings.
Leukemia. 2017;31:534-542.
PubMed Text format Abstract available

SAENZ DT, Fiskus W, Manshouri T, Rajapakshe K, et al
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
Leukemia. 2017;31:678-687.
PubMed Text format Abstract available

QAZILBASH MH, Wieder E, Thall PF, Wang X, et al
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.
Leukemia. 2017;31:697-704.
PubMed Text format Abstract available

STRUSKI S, Lagarde S, Bories P, Puiseux C, et al
NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
Leukemia. 2017;31:565-572.
PubMed Text format Abstract available

STENGEL A, Kern W, Haferlach T, Meggendorfer M, et al
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
Leukemia. 2017;31:705-711.
PubMed Text format Abstract available

MCCRACKEN AN, McMonigle RJ, Tessier J, Fransson R, et al
Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
Leukemia. 2017;31:669-677.
PubMed Text format Abstract available

EDELMANN J, Tausch E, Landau DA, Robrecht S, et al
Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
Leukemia. 2017;31:734-738.
PubMed Text format

February 2017

MEDEIROS BC, Fathi AT, DiNardo CD, Pollyea DA, et al
Isocitrate dehydrogenase mutations in myeloid malignancies.
Leukemia. 2017;31:272-281.
PubMed Text format Abstract available

BURNETT AK, Russell NH, Hills RK, Kell J, et al
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
Leukemia. 2017;31:310-317.
PubMed Text format Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: